Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

7.220 -0.520 (-6.72%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	17,939,243
Open	7.620
Bid (Size)	7.200 (900)
Ask (Size)	7.210 (3,800)
Prev. Close	7.740
Today's Range	7.150 - 7.690
52wk Range	1.950 - 12.43
Shares Outstanding	391,156,513
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Today 9:48 EDT

From Schall Law

Via GlobeNewswire

ImmunityBio 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ImmunityBio, Inc. - IBRX

May 22, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

Performance

YTD	+257.4%	+257.4%
1 Month	-1.0%	-1.0%
3 Month	-26.6%	-26.6%
6 Month	+235.8%	+235.8%
1 Year	+185.4%	+185.4%

More News

IMMUNITYBIO CLASS ACTION DEADLINE TUESDAY MAY 26th: Bragar Eagel & Squire, P.C. Urges Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights Before May 26th

May 22, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.

May 22, 2026

From Lowey Dannenberg, P.C.

Via GlobeNewswire

ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS

May 22, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation

May 22, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX

May 21, 2026

From SkyMedia, LLC

Via GlobeNewswire

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

May 21, 2026

From Schall Law

Via GlobeNewswire

Why ImmunityBio Stock is Soaring Higher Today ↗

May 20, 2026

Via The Motley Fool

INVESTOR DEADLINE ALERT: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP

May 20, 2026

From Kessler Topaz Meltzer & Check, LLP

Via Business Wire

IMMUNITYBIO, INC. INVESTORS WITH LOSSES HAVE UNTIL MAY 26, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

May 20, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

May 19, 2026

From Kahn Swick & Foti, LLC

Via GlobeNewswire

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027

May 19, 2026

From ImmunityBio, Inc.

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX

May 19, 2026

From Pomerantz LLP

Via GlobeNewswire

CLASS ACTION REMINDER: Berger Montague Advises ImmunityBio, Inc. (NASDAQ: IBRX) Investors to Inquire About a Securities Fraud Lawsuit by May 26, 2026

May 19, 2026

From Berger Montague

Via GlobeNewswire

ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026

May 19, 2026

From ImmunityBio, Inc.

Via Business Wire

IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urges Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights Before May 26th

May 18, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

IMMUNITYBIO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

May 18, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

May 18, 2026

From Schall Law

Via GlobeNewswire

ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035

May 18, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States

May 16, 2026

From ImmunityBio, Inc.

Via Business Wire

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

May 14, 2026

From Schall Law

Via GlobeNewswire

IMMUNITYBIO, INC. INVESTORS WITH LOSSES HAVE UNTIL MAY 26, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

May 14, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase

May 14, 2026

Via FinancialNewsMedia

ImmunityBio, Inc. (IBRX) Action Lawsuit: Investors Face May 26, 2026, Deadline

May 13, 2026

Via NewMediaWire

Frequently Asked Questions

Is ImmunityBio, Inc. - Common Stock publicly traded?

Yes, ImmunityBio, Inc. - Common Stock is publicly traded.

What exchange does ImmunityBio, Inc. - Common Stock trade on?

ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for ImmunityBio, Inc. - Common Stock?

The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market

What is the current price of ImmunityBio, Inc. - Common Stock?

The current price of ImmunityBio, Inc. - Common Stock is 7.220

When was ImmunityBio, Inc. - Common Stock last traded?

The last trade of ImmunityBio, Inc. - Common Stock was at 05/22/26 04:00 PM ET

What is the market capitalization of ImmunityBio, Inc. - Common Stock?

The market capitalization of ImmunityBio, Inc. - Common Stock is 2.82B

How many shares of ImmunityBio, Inc. - Common Stock are outstanding?

ImmunityBio, Inc. - Common Stock has 3B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.